Corpus Intelligence IC Memo — BAPTIST HEALTH LOUISVILLE 2026-04-26 04:04 UTC
IC Memo — BAPTIST HEALTH LOUISVILLE
Investment Committee Memorandum | KY | 454 beds | Grade B | EBITDA uplift $49.8M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

BAPTIST HEALTH LOUISVILLE

CCN 180130 | JEFFERSON, KY | 454 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

BAPTIST HEALTH LOUISVILLE is a 454-bed suburban community hospital in JEFFERSON, KY with $677.1M in net patient revenue and a -7.2% operating margin. The hospital serves a payer mix of 35.9% Medicare, 1.3% Medicaid, and 62.7% commercial.

Thesis: Undervalued. Our ML models identify $49.8M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -7.2% to 0.2% (+736bps).

Net Revenue HCRIS$677.1M
Current EBITDA COMPUTED$-48.4M
Operating Margin COMPUTED-7.2%
Occupancy HCRIS68.3%
Revenue / Bed COMPUTED$1.5M
Net-to-Gross HCRIS14.5%
Distress Probability ML42.6%

2. Market Context & Competitive Position

114
KY Hospitals
-0.6%
State Median Margin
10
Comparable Hospitals

KY has 114 Medicare-certified hospitals with a median operating margin of -0.6%. The target's margin of -7.2% places it below the state median. Among 10 size-comparable peers (227-908 beds), the median margin is -4.2%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (227-908), prioritizing same-state peers. 10 hospitals in the comp set.

HospitalStateBedsRevenueMargin
BAPTIST HEALTH LOUISVILLE (Target)KY454$677.1M-7.2%
UOFL HEALTH-LOUISVILLEKY789$1.13B7.8%
ST ELIZABETH HEALTHCAREKY448$1.07B-13.2%
UNIVERSITY OF LOUISVILLE HOSPIKY333$806.1M-6.9%
BAPTIST HEALTH LEXINGTONKY434$760.6M2.8%
OWENSBORO HEALTH REGIONAL HOSPKY302$678.6M11.1%
PIKEVILLE MEDICAL CENTERKY328$555.1M-16.6%
KINGS DAUGHTERS MEDICAL CENTERKY367$542.4M-20.5%
BAPTIST HEALTH HARDINKY259$459.5M-1.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $49.8M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$14.2M+210bp18mo
Cost to Collect4.5%2.5%$13.5M+200bp12mo
Denial Rate Reduction12.0%6.5%$13.4M+198bp12mo
A/R Days Reduction5200.0%3800.0%$8.2M+122bp9mo
Clean Claim Rate88.0%96.0%$433K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$14.2M
Cost to Collect
$13.5M
Denial Rate Reduction
$13.4M
A/R Days Reduction
$8.2M
Clean Claim Rate
$433K
Total EBITDA Uplift$49.8M
Current EBITDA$-48.4M
+ RCM Uplift+$49.8M
Pro Forma EBITDA$1.4M
Current Margin-7.2%
Pro Forma Margin0.2%
WC Released (1x)$26.0M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-74.5M$178.9M0.00x-100.0%
Base (11x exit)10.0x11.0x$-74.5M$172.6M0.00x-100.0%
Bull Case9.0x11.0x$-67.1M$312.8M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-67.1M$321.5M0.00x-100.0%
Bear Case11.0x10.0x$-82.0M$-46.1M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-82.0M$-77.4M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 10 hospitals with 227-908 beds
  • Same-state prioritization (n=11)
  • Comp margins: P25=-15.8% / P50=-4.2% / P75=3.8%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.